ArticleBiology direct2026
A novel synergistic action of phage vB_PaeP_GZMU_A1002 with allicin against carbapenem-resistant Pseudomonas aeruginosa.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characterization of a newly isolated broad-host-range lytic phage WEN7 against multidrug-resistant clinicalFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The increasing problem of bacterial resistance to antibiotics necessitates the exploration of innovative antimicrobial strategies. Phage therapy is a promising solution; however, naturally occurring phages targeting resistant pathogens remain limited. This study aimed to isolate and identify phages that lyse carbapenem-resistant Pseudomonas aeruginosa (CRPA) from sewage and investigate the synergistic antimicrobial effects of phage therapy combined with allicin. A novel phage, vB_PaeP_GZMU_A1002, was successfully isolated and characterized, revealing a double-stranded DNA genome of 63,770 bp with no virulence or resistance genes, indicating its safety for application. This phage demonstrated good stability across various temperatures and pH levels, effectively inhibited the CRPA growth within 12 h, and achieved a biofilm clearance rate of about 50%. Notably, the combination of phage and allicin significantly enhanced antimicrobial efficacy, reducing effective concentrations of both agents. The synergistic action was likely due to increased damage to bacterial cell membranes and reduced cell surface hydrophobicity. This research highlights the potential of phage therapy, particularly when combined with natural compounds like allicin, as a viable approach to combat antibiotic-resistant infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.